Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial

Nicolò Peccatori, Franco Locatelli, Anneke C J Ammerlaan, Yilin Jiang, Vincent H J van der Velden, Andrej Lissat, Anna Nilsson, Bella Bielorai, Barbara De Moerloose, Susana Rives, Alba Rubio-San-Simon, Uta Dirksen, Gernot Engstler, Benedicte Bruno, Cristina Diaz-de-Heredia, Benoit Brethon, Francisco Bautista Sirvent, Fanny Rialland, Lucie Sramkova, Marlène Pasquet, Karsten Nysom, Nicoletta Bertorello, Peter Bader, Jochen Buechner, Inge M van der Sluis, Berna Beverloo, Barbara Sleight, Arend von Stackelberg, Christian Michel Zwaan, Erica Brivio

Open source

DOI: 10.1016/s2352-3026(26)00104-3
Published: 2026-07
Container: The Lancet Haematology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00104-3,
  title = {Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial},
  author = {Nicolò Peccatori and Franco Locatelli and Anneke C J Ammerlaan and Yilin Jiang and Vincent H J van der Velden and Andrej Lissat and Anna Nilsson and Bella Bielorai and Barbara De Moerloose and Susana Rives and Alba Rubio-San-Simon and Uta Dirksen and Gernot Engstler and Benedicte Bruno and Cristina Diaz-de-Heredia and Benoit Brethon and Francisco Bautista Sirvent and Fanny Rialland and Lucie Sramkova and Marlène Pasquet and Karsten Nysom and Nicoletta Bertorello and Peter Bader and Jochen Buechner and Inge M van der Sluis and Berna Beverloo and Barbara Sleight and Arend von Stackelberg and Christian Michel Zwaan and Erica Brivio},
  year = {2026},
  journal = {The Lancet Haematology},
  doi = {10.1016/s2352-3026(26)00104-3},
  url = {https://doi.org/10.1016/s2352-3026(26)00104-3}
}

RIS

TY  - JOUR
TI  - Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial
AU  - Nicolò Peccatori
AU  - Franco Locatelli
AU  - Anneke C J Ammerlaan
AU  - Yilin Jiang
AU  - Vincent H J van der Velden
AU  - Andrej Lissat
AU  - Anna Nilsson
AU  - Bella Bielorai
AU  - Barbara De Moerloose
AU  - Susana Rives
AU  - Alba Rubio-San-Simon
AU  - Uta Dirksen
AU  - Gernot Engstler
AU  - Benedicte Bruno
AU  - Cristina Diaz-de-Heredia
AU  - Benoit Brethon
AU  - Francisco Bautista Sirvent
AU  - Fanny Rialland
AU  - Lucie Sramkova
AU  - Marlène Pasquet
AU  - Karsten Nysom
AU  - Nicoletta Bertorello
AU  - Peter Bader
AU  - Jochen Buechner
AU  - Inge M van der Sluis
AU  - Berna Beverloo
AU  - Barbara Sleight
AU  - Arend von Stackelberg
AU  - Christian Michel Zwaan
AU  - Erica Brivio
PY  - 2026
JO  - The Lancet Haematology
DO  - 10.1016/s2352-3026(26)00104-3
UR  - https://doi.org/10.1016/s2352-3026(26)00104-3
ER  -

APA

Peccatori, N., Locatelli, F., Ammerlaan, A. C. J., Jiang, Y., Velden, V. H. J. V. D., Lissat, A., Nilsson, A., Bielorai, B., Moerloose, B. D., Rives, S., Rubio-San-Simon, A., Dirksen, U., Engstler, G., Bruno, B., Diaz-de-Heredia, C., Brethon, B., Sirvent, F. B., Rialland, F., Sramkova, L., Pasquet, M., Nysom, K., Bertorello, N., Bader, P., Buechner, J., Sluis, I. M. V. D., Beverloo, B., Sleight, B., Stackelberg, A. V., Zwaan, C. M., & Brivio, E. (2026). Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(26)00104-3

Source records

crossref · retrieved 2026-09-25T22:54:59.741Z